Oncologic progression of bone plasmacytomas to multiple myeloma
Autor(a) principal: | |
---|---|
Data de Publicação: | 2006 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Clinics |
Texto Completo: | https://www.revistas.usp.br/clinics/article/view/17523 |
Resumo: | PURPOSE: To evaluate the clinical aspects, diagnoses, prognostic factors, and percent progression of plasmacytoma to multiple myeloma. MATERIALS AND METHODS: 103 medical records of patients suspected of plasmacytoma were surveyed covering the period between 1950 and 1998, and 30 were selected for analysis. Patients were classified into 2 groups: patients who did (n = 17) and did not (n = 13) progress to multiple myeloma. Comparative statistics regarding a variety of clincial aspects were developed. RESULTS: Patients who progressed to multiple myeloma were younger than those who did not (52.3 ± 2.6 vs 62.6 ± 3.4 years; mean ± SEM; P = 0.02). There were no significant differences in gender between groups. A higher incidence of multiple recurrence was observed in patients who progressed to multiple myeloma (75%, P = 0.049). Both groups showed a prevalence of vertebral column injuries. No significant differences were found between groups regarding the disease period (from the onset of symptoms until diagnosis) (P = 0.20) and survival (P = 0.34). The average time to progression from plasmacytoma to myeloma was 41 ± 39 months (mean ± SD), and the progression rate was 57%. CONCLUSION: Patients who progressed to multiple myeloma were younger than those who did not. No significant differences were found between groups regarding sex, time from symptom onset to diagnosis, and survival time. In both groups, the most affected anatomic location was the vertebral column, and most affected sex was male. The average time to progression to multiple myeloma was 41 months. It was not possible to determine the factors that influenced the survival of patients with plasmacytoma or for those who progressed to multiple myeloma. |
id |
USP-19_59f4c0e019e4c393cc0d670159f44901 |
---|---|
oai_identifier_str |
oai:revistas.usp.br:article/17523 |
network_acronym_str |
USP-19 |
network_name_str |
Clinics |
repository_id_str |
|
spelling |
Oncologic progression of bone plasmacytomas to multiple myeloma Evolução oncológica dos plasmocitomas ósseos para mieloma múltiplo PlasmocitomaMieloma MúltiploEvolução clínicaPrognósticoCélulas plasmáticasPlasmacytomaMultiple myelomaClinical progressionPrognosisPlasma cells PURPOSE: To evaluate the clinical aspects, diagnoses, prognostic factors, and percent progression of plasmacytoma to multiple myeloma. MATERIALS AND METHODS: 103 medical records of patients suspected of plasmacytoma were surveyed covering the period between 1950 and 1998, and 30 were selected for analysis. Patients were classified into 2 groups: patients who did (n = 17) and did not (n = 13) progress to multiple myeloma. Comparative statistics regarding a variety of clincial aspects were developed. RESULTS: Patients who progressed to multiple myeloma were younger than those who did not (52.3 ± 2.6 vs 62.6 ± 3.4 years; mean ± SEM; P = 0.02). There were no significant differences in gender between groups. A higher incidence of multiple recurrence was observed in patients who progressed to multiple myeloma (75%, P = 0.049). Both groups showed a prevalence of vertebral column injuries. No significant differences were found between groups regarding the disease period (from the onset of symptoms until diagnosis) (P = 0.20) and survival (P = 0.34). The average time to progression from plasmacytoma to myeloma was 41 ± 39 months (mean ± SD), and the progression rate was 57%. CONCLUSION: Patients who progressed to multiple myeloma were younger than those who did not. No significant differences were found between groups regarding sex, time from symptom onset to diagnosis, and survival time. In both groups, the most affected anatomic location was the vertebral column, and most affected sex was male. The average time to progression to multiple myeloma was 41 months. It was not possible to determine the factors that influenced the survival of patients with plasmacytoma or for those who progressed to multiple myeloma. OBJETIVO: Avaliar os aspectos clínicos, diagnósticos, fatores de prognóstico e porcentagem de evolução dos casos de plasmocitoma para mieloma múltiplo. MATERIAS E MÉTODOS: Foram levantados 103 prontuários do Hospital das Clínicas da FMUSP, entre os anos de 1950 e 1998. Destes, 73 não foram utilizados por perda de seguimento ou por apresentarem diagnóstico diferente de plasmocitoma. RESULTADOS: Concluímos que a idade dos pacientes que evoluíram para mieloma múltiplo é inferior a dos pacientes que não evoluíram. A média do primeiro grupo foi de 52,3 ± 2,6 anos e a do segundo 62,6 ± 3,4 anos (média ± SEM; p=0,02). Não houve diferença estatística quanto ao sexo. Analisando pacientes com plasmocitoma que evoluiu para mieloma múltiplo, foi observada uma incidência maior de recidivas múltiplas (75%, p=0,049). Em ambos os grupos houve predominância de lesões da coluna vertebral. Não houve nenhuma diferença significativa entre os grupos com relação ao tempo de doença (desde o aparecimento dos sintomas até o diagnóstico) (p=0,20) e à sobrevida (p=0,34). Quanto ao tempo de evolução de plasmocitoma para mieloma, a média foi de 41 meses (DP=38,8), com uma taxa de evolução aproximadamente igual a 57%. CONCLUSÃO: Os pacientes que evoluíram para mieloma múltiplo são mais jovens. Não houve diferença significativa entre os dois grupos quanto ao sexo, tempo de doença e tempo de sobrevida. Em ambos os grupos a localização anatômica mais acometida foi a coluna vertebral. O tempo médio de evolução para mieloma múltiplo foi de 41 meses. Não foi possível calcular os fatores que influem na sobrevida dos pacientes com plasmocitoma e dos pacientes com plasmocitoma que evoluiu para mieloma múltiplo. Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo2006-04-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/clinics/article/view/1752310.1590/S1807-59322006000200009Clinics; v. 61 n. 2 (2006); 139-146 Clinics; Vol. 61 Núm. 2 (2006); 139-146 Clinics; Vol. 61 No. 2 (2006); 139-146 1980-53221807-5932reponame:Clinicsinstname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/clinics/article/view/17523/19581Bertanha, FernandaBoufelli, GabrielaCamargo, Olavo Pires deBaptista, André MathiasCaiero, Marcelo TadeuOliveira, Claudia Regina GCM deFilippi, Renéeinfo:eu-repo/semantics/openAccess2012-05-22T18:06:15Zoai:revistas.usp.br:article/17523Revistahttps://www.revistas.usp.br/clinicsPUBhttps://www.revistas.usp.br/clinics/oai||clinics@hc.fm.usp.br1980-53221807-5932opendoar:2012-05-22T18:06:15Clinics - Universidade de São Paulo (USP)false |
dc.title.none.fl_str_mv |
Oncologic progression of bone plasmacytomas to multiple myeloma Evolução oncológica dos plasmocitomas ósseos para mieloma múltiplo |
title |
Oncologic progression of bone plasmacytomas to multiple myeloma |
spellingShingle |
Oncologic progression of bone plasmacytomas to multiple myeloma Bertanha, Fernanda Plasmocitoma Mieloma Múltiplo Evolução clínica Prognóstico Células plasmáticas Plasmacytoma Multiple myeloma Clinical progression Prognosis Plasma cells |
title_short |
Oncologic progression of bone plasmacytomas to multiple myeloma |
title_full |
Oncologic progression of bone plasmacytomas to multiple myeloma |
title_fullStr |
Oncologic progression of bone plasmacytomas to multiple myeloma |
title_full_unstemmed |
Oncologic progression of bone plasmacytomas to multiple myeloma |
title_sort |
Oncologic progression of bone plasmacytomas to multiple myeloma |
author |
Bertanha, Fernanda |
author_facet |
Bertanha, Fernanda Boufelli, Gabriela Camargo, Olavo Pires de Baptista, André Mathias Caiero, Marcelo Tadeu Oliveira, Claudia Regina GCM de Filippi, Renée |
author_role |
author |
author2 |
Boufelli, Gabriela Camargo, Olavo Pires de Baptista, André Mathias Caiero, Marcelo Tadeu Oliveira, Claudia Regina GCM de Filippi, Renée |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Bertanha, Fernanda Boufelli, Gabriela Camargo, Olavo Pires de Baptista, André Mathias Caiero, Marcelo Tadeu Oliveira, Claudia Regina GCM de Filippi, Renée |
dc.subject.por.fl_str_mv |
Plasmocitoma Mieloma Múltiplo Evolução clínica Prognóstico Células plasmáticas Plasmacytoma Multiple myeloma Clinical progression Prognosis Plasma cells |
topic |
Plasmocitoma Mieloma Múltiplo Evolução clínica Prognóstico Células plasmáticas Plasmacytoma Multiple myeloma Clinical progression Prognosis Plasma cells |
description |
PURPOSE: To evaluate the clinical aspects, diagnoses, prognostic factors, and percent progression of plasmacytoma to multiple myeloma. MATERIALS AND METHODS: 103 medical records of patients suspected of plasmacytoma were surveyed covering the period between 1950 and 1998, and 30 were selected for analysis. Patients were classified into 2 groups: patients who did (n = 17) and did not (n = 13) progress to multiple myeloma. Comparative statistics regarding a variety of clincial aspects were developed. RESULTS: Patients who progressed to multiple myeloma were younger than those who did not (52.3 ± 2.6 vs 62.6 ± 3.4 years; mean ± SEM; P = 0.02). There were no significant differences in gender between groups. A higher incidence of multiple recurrence was observed in patients who progressed to multiple myeloma (75%, P = 0.049). Both groups showed a prevalence of vertebral column injuries. No significant differences were found between groups regarding the disease period (from the onset of symptoms until diagnosis) (P = 0.20) and survival (P = 0.34). The average time to progression from plasmacytoma to myeloma was 41 ± 39 months (mean ± SD), and the progression rate was 57%. CONCLUSION: Patients who progressed to multiple myeloma were younger than those who did not. No significant differences were found between groups regarding sex, time from symptom onset to diagnosis, and survival time. In both groups, the most affected anatomic location was the vertebral column, and most affected sex was male. The average time to progression to multiple myeloma was 41 months. It was not possible to determine the factors that influenced the survival of patients with plasmacytoma or for those who progressed to multiple myeloma. |
publishDate |
2006 |
dc.date.none.fl_str_mv |
2006-04-01 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/17523 10.1590/S1807-59322006000200009 |
url |
https://www.revistas.usp.br/clinics/article/view/17523 |
identifier_str_mv |
10.1590/S1807-59322006000200009 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
https://www.revistas.usp.br/clinics/article/view/17523/19581 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
publisher.none.fl_str_mv |
Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo |
dc.source.none.fl_str_mv |
Clinics; v. 61 n. 2 (2006); 139-146 Clinics; Vol. 61 Núm. 2 (2006); 139-146 Clinics; Vol. 61 No. 2 (2006); 139-146 1980-5322 1807-5932 reponame:Clinics instname:Universidade de São Paulo (USP) instacron:USP |
instname_str |
Universidade de São Paulo (USP) |
instacron_str |
USP |
institution |
USP |
reponame_str |
Clinics |
collection |
Clinics |
repository.name.fl_str_mv |
Clinics - Universidade de São Paulo (USP) |
repository.mail.fl_str_mv |
||clinics@hc.fm.usp.br |
_version_ |
1787713167757934592 |